drug · small molecule
PHVS-416
Phase 3updated 5mo agoby Pharvaris NV🔗 ChEMBL
Phase 3community read0 votes
Small molecule drug with a maximum clinical stage of Phase 3, with 1 investigational indication.
all catalysts(0)
nothing on the calendar yet
Trials studying PHVS-416
- phase3Study of Oral Deucrictibant XR Tablet for Prophylaxis and Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adults With Acquired Angioedema Due to C1 Inhibitor Deficiency
- phase3Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE
- phase2Dose-ranging Study of Oral PHA-022121 for Prophylaxis Against Angioedema Attacks in Patients With Hereditary Angioedema Type I or Type II
- —EAP for Deucrictibant Immediate-release
- phase3Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema
- phase3Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE
- phase2Dose-ranging Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema
- phase3Study of Oral Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema
News(3)
- Roivant surges on ‘exceptional’ results; Bristol Myers touts first-of-its-kind CAR-T therapyOne analyst views Roivant’s pulmonary hypertension drug as a future $10 billion-plus seller. Elsewhere, AstraZeneca overcame a negative advisory committee vote and Pharvaris claimed success in a ke…biopharma_dive · 25d ago
- Pharvaris' stock jumps on pivotal success in rare genetic diseasePharvaris claims it achieved “injectable-like efficacy” in a once-daily pill for a debilitating genetic disease. The experimental drug, an extended-release version of deucrictibant, is designed to…endpoints · 25d ago
- Pharvaris' latest phase 3 win builds case for HAE drug with FDA verdict pendingPharvaris’ deucrictibant has tasted success in a second phase 3 study, strengthening the case for the therapy to treat hereditary angioedema patients as the Swiss biotech awaits an FDA approval dec…fiercebiotech · 25d ago
Data sources
last refreshed 26m ago
Found something off?
comments(0)
5-min edit window · permanent after that